Evercore ISI Raises Price Target for argenx (ARGX)
On May 15, 2026, Evercore ISI analyst Gavin Clark-Gartner raised the price target on argenx SE (NASDAQ:ARGX) to $1,059 from $1,007 while maintaining an Outperform rating. This follows a recent FDA label expansion for Vyvgart and Vyvgart Hytrulo in generalized myasthenia gravis, which broadens the addressable patient population by approximately 11,000 patients.
Tickers: $ARGX